Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma
Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma
复制标题
术后血清 CA19-9、CEA 和 CA125 预测胰腺癌根治术后辅助放化疗的反应
DOI：
10.1016/j.pan.2018.05.479
复制
发表时间：
2018-09-01
期刊：
影响因子：
3.6
通讯作者：
Liu, Liang
中科院分区：
文献类型：
--
作者：
Xu, Hua-Xiang;Li, Shuo;Liu, Liang
目的：目的：探讨术后血清CA 19 -9、CA 125、CEA水平对辅助放化疗疗效的预测价值。方法：对804例胰腺癌根治术患者术后血清CA 19 -9、CA 125、CEA水平与辅助放化疗疗效的关系进行分析。辅助放化疗是晚期复发[12.2 vs. 8.5个月，P = 0.001]和长期生存[23.7 vs. 17.0个月，P = 0.001]的独立因素。
Objective: To evaluate the prediction of benefits from adjuvant chemoradiotherapy by postoperative serum CA19-9, CA125 and CEA.Methods: The relations between benefits from adjuvant chemoradiotherapy and levels of postoperative serum CA19-9, CA125 and CEA were investigated in 804 pancreatic adenocarcinoma patients who received radical resection.Results: Adjuvant chemoradiotherapy was an independent factor for late recurrence [12.2 vs. 8.5 months, P = 0.001 for recurrence free survival (RFS)] and long survival [23.7 vs. 17.0 months, P